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Abstract
Aims: Our aims were to examine the effects of a simultaneous stimulation of b2-adrenergic receptors and
inhibition of uterine phosphodiesterases (PDE), in the pregnant rat uterus in vivo and on human uterine tissue
in vitro. We also set out to measure cAMP levels and detect the expressions of the isoenzymes PDE4B and
PDE4D in human uterine tissue samples.
Material and Methods: Preterm birth was induced in Sprague-Dawley rats with bacterial lipopolysaccharide.
The uterine effects of terbutaline alone or in combination with rolipram were tested in vivo. Human myometrial
strips from cesarean sections at full-term pregnancy and at preterm labor were stimulated with oxytocin, and
the inhibitory effects of theophylline, rolipram and terbutaline were studied. The myometrial accumulation of
cAMP in the presence of rolipram and terbutaline was determined by enzyme immunoassay. The expressions
of PDE4B and PDE4D proteins were detected by Western blotting.
Results: The selective PDE4 inhibitor rolipram was more effective than the non-selective PDE inhibitor
theophylline in inhibiting the oxytocin-induced contractions in the human uterus. The uterus-relaxing effects
of low doses of terbutaline were markedly potentiated by rolipram, both in rats and in human tissues. The
changes in uterine cAMP levels correlated with these results. At preterm labor, PDE4B was the predominant
form of PDE4 expressed; at full term, PDE4D was expressed more strongly.
Conclusions: A combination of selective PDE4 inhibitors and b2-agonists should be considered for the
treatment of preterm contractions.
Key words: b2-mimetics, phosphodiesterase, preterm labor, rolipram, terbutaline.
Introduction
Preterm birth, often associated with genital inflamma-
tion, is the leading cause of perinatal mortality and
morbidity.1 Although the management of threate-
ned preterm labor by tocolytic therapy can prolong
gestation,2 evidence regarding its efficacy is limited.
A major signaling pathway implicated in maintain-
ing myometrial relaxation is the cAMP/cAMP-
dependent protein kinase A (PKA) pathway.3 While
b2-adrenergic receptor (b2-AR) agonists stimulate the
generation of cAMP in the myometrium,4 and hence
are commonly used to treat preterm labor, local pho-
sphodiesterases (PDE) ensure the termination of sig-
naling by the degradation of cAMP to the inactive
5′-AMP.5
PDE4 (formerly known as cAMP-PDE) is the pre-
dominant isoenzyme in the majority of inflammatory
cells and in the human myometrium.6 The four geneti-
cally distinct PDE4 subtypes, termed PDE4A-D,7 are
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encoded by alternative mRNA splices, involving at
least 35 different PDE4 proteins.8 In the early 1970s,
rolipram, a cAMP-PDE inhibitor, was developed as an
antidepressant, although its side-effects (nausea and
gastrointestinal disturbances) ruled out its clinical
development.7 Emesis is associated with the inhibition
of PDE4D,9 while PDE4B has been shown to be
required for lipopolysaccharide (LPS)-evoked inflam-
matory responses. LPS, an endotoxin of gram-negative
bacteria, causes preterm birth in animals and has been
implicated as a factor triggering preterm labor in
humans.10 The prototype selective PDE4 inhibitor
rolipram and also b-AR agonists have been reported to
modulate the production of inflammatory mediators.11
In a previous study, we demonstrated that rolipram
potentiated the uterus-relaxing effect of the b2-AR
agonist terbutaline in intact and in LPS-treated rats in
vitro, the most pronounced relaxation being detected in
LPS-treated rats. In the present study, we investigated
the tocolytic effects of rolipram and terbutaline in intact
and LPS-treated late-pregnant rats in vivo and on
human uterine specimens in vitro. Cyclic AMP levels
and the expressions of PDE4B and PDE4D proteins
were also determined in human uterine tissues from
term and preterm labor.
Methods
Animals
Animals were treated in accordance with the European
Communities Council Directives (86/609/ECC) and
the Hungarian Act for the Protection of Animals
in Research (XXVIII.tv.32.§). Experiments involving
animal subjects were carried out with the approval of
the Hungarian Ethical Committee for Animal Research
(registration number: IV./01758-2/2008).
Sexually mature female Sprague-Dawley rats (body
mass: 140–160 g, 50–60 days old) were mated in the
early morning hours. Copulation was confirmed by
the presence of a copulation plug or spermatozoa in the
vagina. The day of copulation was considered to be the
first day of pregnancy. The animals were housed in
temperature- (20–23°C), humidity- (40–60%) and light-
(12 h of light, 12 h of dark) regulated rooms, with water
and food intake available ad libitum.
In vivo treatments
The animals were divided into two groups (n = 10 in
each): (i) intact pregnant rats on day 22 of pregnancy
(full term); and (ii) rats treated with LPS (i.p. 125 mg/
day; Sigma-Aldrich, Budapest, Hungary) for 3 consecu-
tive days from day 18 of pregnancy, in the early morning
hours, to evoke preterm birth, which occurred in the
early afternoon of day 20.12
In vivo myographic studies
The in vivo myographic studies were done on intact rats
(on day 22 of pregnancy; at full term) and on LPS-
treated rats (on day 20 of pregnancy; at preterm), in the
morning hours between 08.00 and 10.00 hours. Rats
were anesthetized with a mixture of ketamine and xyla-
zine (36 and 4 mg/kg, respectively) i.p.; and the jugular
vein was cannulated for i.v. drug administration. After
laparotomy, the left uterine horn was exposed, and an
implantable force/displacement transducer (SEN-04-
FSG2; Experimetria, Budapest, Hungary) was sutured
onto the myometrial surface, leaving the amniotic
membranes untouched. There was no leak of amniotic
fluid during the experiments. The animals with the
sensors were then placed into a Faraday cage made
from iron to filter out environmental electromagnetic
noise.
The mechanical displacements elicited by the con-
tractions of the uterus were converted to electri-
cal impulses by the transducer, and amplified by a
bridge amplifier (AMP-01-SG, Experimetria, Budapest,
Hungary). The amplified electric signal was detec-
ted and analyzed by the S.P.E.L. Advanced ISOSYS
Data Acquisition System (Experimetria, Budapest,
Hungary). The basal tone was registered for 4 min. The
area under the curve (AUC) of this 4 min was always
used as the control, and the inhibition was calculated as
the percentage of this initial period. The AUC of 4-min
periods were evaluated; the effects of terbutaline or the
terbutaline + rolipram were expressed as percentages
of the spontaneous activity.
Doses of terbutaline (Sigma-Aldrich, Budapest,
Hungary), and rolipram (Sigma-Aldrich, Budapest,
Hungary), were administered i.v. and the contraction
signals were recorded. Two 0.5 mg/kg doses of terbuta-
line were followed by 10 doses of 1 mg/kg at 5-min
intervals; 0.25 mg/kg of rolipram was administered
similarly to terbutaline alone. In combination, rolipram
was given in a single dose of 500 mg/kg. The applied
dose was chosen upon the dose-response curve of
rolipram, hence the dose eliciting 30% relaxation. This
dose (500 mg/kg) is in accordance with some previous
in vivo studies done on rats.13,14
In vitro contractility studies
Thirty biopsy specimens of human myometrial tissue
were obtained at cesarean section in the third trimester
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of pregnancy in two groups: at full-term pregnancy
(37–41 weeks of gestation; n = 19) and at preterm birth
(32–36 weeks; n = 11). At full-term pregnancy cesarean
delivery was indicated by a previous cesarean delivery,
breech presentation, suspected cephalopelvic dispro-
portion or myopia. Parity varied from 0 to 3, and mean
maternal age was 30.8 years (22–41 years). None of the
women received a tocolytic agent, and there were no
signs of labor.
Preterm delivery occurred in mothers with twin
pregnancies, or labor was indicated by an ongoing
infection, leukocytosis, toxemia, fetal distress or
growth restriction. In the preterm group, parity varied
from 0 to 3, mean maternal age was 32.7 years (26–
42 years). Three out of 11 patients received tocolytic
therapy (magnesium sulfate) to arrest preterm uterine
contractions, which proved to be ineffective. All the
operations were performed under spinal anesthesia.
The Ethical Committee of the University of Szeged
approved the clinical protocol (registration number:
114/2009).
Tissue samples (10 ¥ 10 ¥ 20 mm) from the upper
edge of a lower-segment transverse incision were cut
after delivering the child, but before oxytocin was
given to the mothers. Tissues were stored in Krebs–
Henseleit solution (containing in mM: 118 NaCl, 5 KCl,
2 CaCl2, 0.5 MgSO4, 1 K2SO4, 25 NaHCO3, 10 glucose;
pH 7.4) at 4°C, and were taken into the experiment
within 12 h of collection. Each tissue was cut into at
least four strips (app. 3 ¥ 5 ¥ 10 mm), mounted verti-
cally in an organ bath (Krebs–Henseleit solution at
37°C; perfused with 95% O2 + 5% CO2), and tested in
parallel. After mounting, the strips were equilibrated
for ~2 h before experiments were undertaken, with a
solution change every 15 min. The specimens exhibited
spontaneous contractions over the incubation period.
The initial tension was set to 3.00 g, which was relaxed
to 1.5 g at the end of equilibration. The tension of the
myometrial strips was measured with an isometric
force transducer (SG-02; Experimetria, Budapest,
Hungary) and recorded with an S.P.E.L. Advanced
ISOSYS Data Acquisition System.
Rhythmic contractions were elicited by 10-6 M oxy-
tocin. After stimulation, theophylline, rolipram, or
terbutaline was added in a non-cumulative manner.
After each concentration of the tested drug, the strips
were washed three times, allowed to recover for 5 min,
and then contracted again with oxytocin. Slight tissue
fatigue was observed only before the very last dose
which did not influence our measurements signifi-
cantly. The effect of terbutaline was also tested in the
presence of 10-6 M rolipram. AUC of 4-min periods
were evaluated; the effects of rolipram and terbutaline
were expressed as percentages of the oxytocin-induced
contractions.
Measurement of uterine cAMP accumulation
Human uterine tissue samples from full-term preg-
nancy and preterm birth were incubated under the
same conditions in an organ bath as described above.
Basal cAMP accumulations were detected in the pres-
ence of rolipram only (10-6 M; 10 min). In the presence
of rolipram (10-6 M; 10 min), the cAMP accumulation
was stimulated by terbutaline (10-8; 10-6; 10-4 M;
10 min) and finally forskolin was added to the bath
(10-5 M; 10 min). After stimulation, the samples were
immediately frozen in liquid nitrogen in which they
were stored until the extraction of cAMP.15 Uterine
cAMP accumulation was measured with a cAMP EIA
Kit (Sigma-Aldrich, Budapest, Hungary) and tissue
cAMP levels were expressed in pmol/mg tissue.
Western blotting
Proteins from human uterine specimens were isolated
with the Macherey-Nagel Nucleospin Kit (Izinta,
Budapest, Hungary) according to the manufacturer’s
instructions. Protein concentrations were determined
by BioSpec-nano (Shimadzu, Budapest, Hungary).
Sixty micrograms of protein per well was subjected to
electrophoresis on 4–12% NuPAGE Bis-Tris Gel in
XCell SureLock Mini-Cell Units (Invitrogen, Hungary).
Proteins were transferred from gels onto nitrocellulose
membranes, using the iBlot Gel Transfer System (Invit-
rogen, Hungary). The blots were incubated on a shaker
with PDE4B, PDE4D and b-actin polyclonal antibodies
(Santa Cruz Biotechnology, CA, USA; 1:200) in the
blocking buffer, immunoreactivity was detected with
the WesternBreeze Chromogenic Western blot immu-
nodetection kit (Invitrogen, Hungary). The optical
density (OD) of each immunoreactive band was deter-
mined with Kodak 1D Images analysis software. OD
values were calculated in arbitrary units after local area
background subtraction.
Statistical analyses
In the animal and human contractility studies, AUC
were evaluated statistically and maximal inhibitory
effects (Emax) were calculated with the Prism 4.0
(Graphpad Software Inc. San Diego, CA, USA) com-
puter program. For statistical evaluations, data were
analyzed by use of the unpaired t-test or one-way
anova tests with the Newman–Keuls post-test.
b2-agonists and PDE inhibitors on uterus
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Results
In vivo contractility studies in rats
The effects of the b2-agonist terbutaline and rolipram
were investigated in vivo. The contractions were inhib-
ited dose-dependently by both compounds. Maximal
inhibitory effect of rolipram in intact rats was
96.7  3.1 standard error of the mean (SEM)%
(IC50 = 0.8  0.1 mg/kg; Fig. 1a). The maximal inhibi-
tions achieved with terbutaline + rolipram were not
statistically different in intact rats on day 22 of preg-
nancy (86.1  8.9 SEM%; Fig. 1b) and in LPS-treated
rats on day 20 (89.0 9.5 SEM%; Fig. 1c). In case of the
combination, rolipram (500 mg/kg i.v.) potentiated the
effect of terbutaline, and this effect primarily prevailed
at the low doses of terbutaline. In the presence of rolip-
ram and at the lowest dose of terbutaline (0.5 mg/kg),
however, the inhibition of the contractions was signifi-
cantly higher (P < 0.001) in the LPS-treated rats
(48.1  4.7 SEM%; Fig. 1c) than in the intact rats
(33.3 1.4 SEM%; Fig. 1b).
In intact rats at term, the IC50 values for terbutaline
(IC50 = 2.94  1.31 mg/kg) were not different from the
combination of terbutaline and rolipram (IC50 =
3.53  1.54 mg/kg). Similarly, in the LPS-treated rats on
day 20, the IC50 values for terbutaline (IC50 =
2.69  0.98 mg/kg) were not different from the combi-
nation of terbutaline and rolipram (IC50 = 5.05
2.71 mg/kg).
In vitro contractility studies in human
uterine samples
Uterine activity was characterized by the AUC of
the concentration-response curves of human uterine
strips. Time control experiments revealed that the
oxytocin-stimulated contractions did not decrease sig-
nificantly through the experiment. Theophylline and
rolipram reduced the oxytocin-induced contractions
by 24.9  3.6 SEM%, and 61.9  4.5 SEM%, respec-
tively. The contraction-inhibiting effect of rolipram
was significantly greater than that of theophylline
(P < 0.001) (Fig. 2).
The effects of the combination of terbutaline and
rolipram were also tested. Whereas terbutaline alone
inhibited the oxytocin-stimulated contractions by
71.6 4.5 SEM%, at full-term pregnancy, in the addi-
tional presence of 10-6 M rolipram, the contractions
were inhibited by 78.3 4.7 SEM% (Fig. 3a). At
preterm birth, the maximum contraction-inhibiting
effect of terbutaline alone was 39.7 4.6 SEM%, but
this was increased to 63.5 4.7 SEM% in the presence
Figure 1 Effect of rolipram on the contraction-inhibiting
effect of terbutaline, in vivo. Contraction-inhibiting
effects are expressed as percentages of the spontaneous
uterine activity. (a) On the basis of the dose-response
curve of rolipram, we determined the sufficient dose of
rolipram to potentiate the contraction-inhibiting effect
of terbutaline. In the presence of ( ) 500 mg/kg rolip-
ram, the contraction-inhibiting effects of 0.5–11 mg/kg
terbutaline were significantly higher in low dose both
in (b) intact rats on day 22 and in (c) LPS-treated rats on
day 20 of pregnancy than the effects of () terbutaline
alone. Group comparisons were made by unpaired
t-test. n = 10 in each group; *P < 0.05, **P < 0.01,
***P < 0.001.
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of rolipram. The effect of 10-10 M terbutaline was more
than doubled in the presence of 10-6 M rolipram
(P < 0.001) (Fig. 3b).
cAMP levels in human uterine samples
The cAMP levels in human uterine tissue samples from
preterm birth and from full-term pregnancy were mea-
sured in the presence of 10-8, 10-6, 10-4 M terbutaline in
combination with 10-6 M rolipram. Basal cAMP levels
(10-6 M rolipram only) were not significantly different
between the term pregnant and preterm birth groups.
There was a concentration-dependent increase of the
terbutaline stimulated cAMP levels in both groups. At
10-6 M concentration, terbutaline elicited significant
elevation of the cAMP levels (P < 0.01) as compared to
the basal level, in the preterm birth group. Besides, at
10-8 M concentration terbutaline elicited significant
elevation of the cAMP levels (P < 0.01) as compared to
the basal level, in both the full-term and the preterm
groups. In the preterm birth samples the cAMP levels
were significantly higher (P < 0.05) in the presence of
10-6 M terbutaline, than in those from full-term preg-
nancy. There were no significant differences between
the groups at 10-8 M or 10-4 M terbutaline (Fig. 4).
Western blot studies
Western blot analysis revealed the presence of PDE4B
and PDE4D in the uterine tissues from term and
preterm labor. The expression of PDE4B (Fig. 5a) was
significantly higher at preterm labor than at full-term
pregnancy. The OD of PDE4D, however, was signi-
ficantly higher in the uterine tissues from the term
pregnancies (Fig. 5b) than at preterm labor.
Discussion
In view of the relatively high rates of adverse maternal
and fetal events during tocolysis, and in the hope of
Figure 2 Effects of selective and non-selective phos-
phodiesterase inhibitors on human uterine contrac-
tions at full-term pregnancy, in vitro. The contractions
were elicited with 10-6 M oxytocin and inhibited with
() 10-11–10-5 M rolipram and () theophylline. Group
comparisons were made by unpaired t-test. n = 3 in
each group; **P < 0.01, ***P < 0.001.
Figure 3 Effects of rolipram on the contraction-
inhibiting effects of terbutaline, in vitro. The contrac-
tions were elicited with 10-6 M oxytocin on human
uterine samples. The contraction-inhibiting effects of
10-10–10-4 M terbutaline were investigated () alone or
( ) in combination with 10-6 M rolipram at (a) full-term
pregnancy and at (b) preterm birth. Group compari-
sons were made by unpaired t-test. n = 3 in each group;
*P < 0.05, **P < 0.01, ***P < 0.001.
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improving the perinatal outcome, there is growing
interest in experimental studies in the use of different
drug combinations. Numerous experiments have sug-
gested the combinations of tocolytic agents, such as the
PDE5 inhibitor sildenafil with the Ca2+ channel blocker
nifedipine,16 the oxytocin antagonist atosiban with
progesterone,17 b2-AR agonists with nifedipine,18 and
b2-AR agonists with gestagens.19 We have now tested
the tocolytic effects of combinations of the b2-AR
agonist terbutaline and the PDE4 inhibitor rolipram.
Figure 4 Intracellular cAMP levels stimulated by 10-5 M
forskolin, in the presence of 10-6 M rolipram and 10-8,
10-6 or 10-4 M terbutaline in human uterine tissue
samples from ( ) full-term pregnancy and ( ) preterm
birth. Basal cAMP levels (10-6 M rolipram alone) were
not significantly different between the term pregnant
and preterm birth groups. In the preterm birth group,
at 10-6 M, terbutaline elevated cAMP levels (P < 0.01)
relative to the basal level. At 10-8 M, terbutaline
elevated cAMP levels (P < 0.01) as compared to the
basal level, in both groups. At 10-6 M terbutaline, the
cAMP levels were higher (*P < 0.05) in the preterm
birth samples than in those from full-term pregnancy.
These results were analyzed by using one-way anova
with the Dunnett post-test. n = 3 in each group.

Figure 5 Changes in PDE4B and PDE4D levels in human
uterine samples at full-term pregnancy and at preterm
birth. The expression of (a) PDE4B was significantly
higher at preterm labor than at full-term pregnancy
(**P < 0.01). The expression of PDE4D was significantly
higher in the uterine tissues from (b) term pregnancies
than at preterm labor (*P < 0.05). Group comparisons
were made by unpaired t-test. n = 4 in each group.
J. Verli et al.
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The b2-AR agonists exert an immediate and profound
relaxing effect on the uterine smooth muscle.20 Recently
published systematic reviews (Lancet, Cochrane Data-
base) agree that b2-AR agonists can delay delivery by
48 h, but long-lasting therapy with b2-AR agonists often
fails. The reasons why long-term administration fre-
quently leads to a poorer therapeutic outcome are a
drug-induced desensitization of the b2-AR, and the
physiological changes in late pregnancy.21,22 Despite
their unfavorable side-effects (tachycardia and the risk
of pulmonary hypertension), the b2-AR agonists still
have an irreplaceable role in tocolytic therapy.23,24
On the other hand, the potential beneficial effect of
the PDE4 selective inhibitor rolipram as a tocolytic
agent has not yet been confirmed. We earlier provided
evidence that rolipram potentiates the tocolytic effect
of terbutaline both in intact and in LPS-treated preg-
nant rats, due to the higher cAMP levels.25 In the
present study, we set out to investigate their effects
on pregnant rats in vivo. Detection of the myometrial
activity in vivo is accompanied by the benefit of allow-
ing studies of the efficacy of these drugs accord-
ing to the principles of integrative pharmacology.26
Experiments on anesthetized rats revealed that the
co-administration of rolipram potentiated the uterus-
relaxing effect of terbutaline. This effect was more pro-
nounced at lower terbutaline doses. The extent of
relaxation achieved with the first dose of terbutaline
was 2–2.5 times higher in the intact and in the LPS-
treated rats, respectively, when it was co-administered
with rolipram. As regards the first three doses of
terbutaline, the combination was more effective at the
time of LPS-induced preterm labor than at normal
term, which is in accordance with our earlier in vitro
findings.
In human experiments, theophylline exerted a very
limited effect, similarly to previous studies on PDE4-
transfected cells.27 The selective PDE4 inhibitor rolip-
ram, however, proved to be much more effective in
inhibiting oxytocin-induced uterine contractions. These
results correspond with earlier findings on the human
uterus in full-term pregnancy.6,28–31 Bardou et al. repor-
ted at first that PDE inhibitors potentiate the effects of
b2-AR agonists in the human near-term myometrium
in vitro.28 Franova et al. investigated the in vitro effects
of the combination of rolipram and the b2-AR agonist
salbutamol, both given in a single dose of 10-4 M, on
the human myometrium at term.32 They found that
the oxytocin-induced contractions were inhibited by
about 70% by the combination of these two drugs,
although the applied doses were very high. Neverthe-
less, no study has been performed with rolipram and
terbutaline on human samples from preterm birth.
Rolipram also potentiated the uterus-relaxing effect
of terbutaline in the term and preterm human uterus,
its effect being most pronounced at lower terbutaline
concentrations and at preterm birth. The findings con-
cerning the tissue cAMP levels were in harmony with
the results of the in vitro contractility assays, suggesting
that the main interaction occurs at an intracellular
cAMP level.
Previous studies have demonstrated that the four
PDE4 subtypes are expressed in the cytosolic fraction
of the human term myometrium,6 and PDE4-selective
inhibitors have been reported to exhibit greater effi-
cacy on the pregnant than on the non-pregnant myo-
metrium.31 The isoenzymes of PDE4 play a role in
inflammatory processes,32 but there are as yet no data
as to whether these proteins are expressed in the
preterm human uterus. Our Western blot study dem-
onstrated the upregulation of PDE4B in human
samples at preterm birth. This might well be a conse-
quence of ongoing inflammatory processes leading
to preterm labor. Intrauterine infection has been
recognized as the primary cause of preterm delivery.33
At preterm birth, the expression of PDE4D was less
pronounced than that of PDE4B, which is similar to
earlier findings at term.34 Thus, the inhibition of
PDE4D is probably not required for effective tocolysis,
which would allow the development of PDE4B-
selective inhibitors, with the benefit of no adverse
emetic effects.
b2-AR agonists and PDE4 inhibitors may be of great
value for tocolysis, given that they both relieve inflam-
mation and prolong pregnancy.33 Although the expres-
sion of PDE4 has been reported in the cardiac
ventricles, PDE4 inhibitors did not produce any posi-
tive inotropic effects, which is a typical action of PDE3
inhibitors.35 Besides the favorable tocolytic effect of the
above combination, a lower incidence of cardiac side-
effects may also be expected.
Given the low frequency of premature cesarean
sections, we believe that every premature sample
should be regarded as an almost unique possibility
for research. We acknowledge that our sample size is
relatively low, and the reasons for such an interven-
tion are diverse. Yet, in spite of the diverse pathology,
the expressions of PDE4B were always higher in the
preterm tissues, which suggests that this enzyme may
be considered a crucial target for drug development.
We conclude that putative therapeutic combinations
of b2-AR agonists and selective PDE4 inhibitors may
b2-agonists and PDE inhibitors on uterus
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enhance the efficacy of human tocolytic therapy. Rolip-
ram alone displays a strong inhibitory effect in vivo,
although, in human therapy such a high dose may
lead to severe side-effects. On the other hand, the
co-administration of rolipram in a low dose with terb-
utaline resulted in a uterus relaxation equivalent to that
of rolipram alone. Such drug combinations may also
have the benefit of allowing the administration of
lower doses of b2-AR agonists, thereby delaying the
desensitization of b2-AR receptors. We presume that
the development of new PDE4B-selective inhibitors
may further enhance the efficacy of tocolysis.
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